Renexxion
  • Home
  • Company
    • Our Vision
    • Our Leadership Team
  • ​Naronapride (ATI-7505)
    • About Naronapride (ATI-7505)
    • Mechanism of Action
    • Development Status
    • Chemistry and Manufacturing
    • Latest Regulatory Developments
  • Knowledge Center
    • Chronic Idiopathic Constipation
    • Irritable Bowel Syndrome
    • ​GERD
    • Functional Dyspepsia
    • Gastroparesis
    • Other Therapeutic Indications
  • News
    • Press >
      • Sinovant Sciences and Renexxion Form Partnership to Develop Naronapride in China BEIJING, SHANGHAI, and Menlo Park
      • Renexxion Achieves Positive FDA Guidance for Phase 3 ready GI Drug Naronapride
  • Contact

Irritable Bowel Syndrome

IBS is a set of chronic symptoms associated with the lower gastrointestinal tract. It is usually experienced as abdominal pain, bloating, and discomfort. IBS can include constipation with difficult or painful bowel movements (IBS-c) or it can include diarrhea due to excess fluid in the colon (IBS-d). While the causes of IBS-c are still in question, lack of colonic motility is thought to be a primary cause. As with chronic constipation, IBS-c can be targeted with naronapride. An estimated 5.5 million adults in the United States suffer from IBS with constipation while an estimated 28 million adults suffer from IBS with intermittent constipation.
Privacy Policy & Terms of Use 
​Copyright Renexxion 2016. All rights reserved.
  • Home
  • Company
    • Our Vision
    • Our Leadership Team
  • ​Naronapride (ATI-7505)
    • About Naronapride (ATI-7505)
    • Mechanism of Action
    • Development Status
    • Chemistry and Manufacturing
    • Latest Regulatory Developments
  • Knowledge Center
    • Chronic Idiopathic Constipation
    • Irritable Bowel Syndrome
    • ​GERD
    • Functional Dyspepsia
    • Gastroparesis
    • Other Therapeutic Indications
  • News
    • Press >
      • Sinovant Sciences and Renexxion Form Partnership to Develop Naronapride in China BEIJING, SHANGHAI, and Menlo Park
      • Renexxion Achieves Positive FDA Guidance for Phase 3 ready GI Drug Naronapride
  • Contact